IRIDEX Corporation reported preliminary unaudited financial results for the fourth quarter (Q4) and full year (FY) ended January 3, 2026. For Q4 2025, total revenue is expected to be between USD 14.6 million and USD 14.8 million, reflecting a year-over-year increase of 15 to 17 percent. The company achieved positive cash flow in Q4 2025. During the quarter, IRIDEX Corporation sold 15,800 Cyclo G6 probes and 44 Cyclo G6 Glaucoma Laser Systems. For the full year 2025, total revenue is expected to be between USD 52.5 million and USD 52.7 million, an increase of 8 percent compared to the prior year. The company expects to achieve positive adjusted EBITDA for the year. Full year sales included 57,700 Cyclo G6 probes and 133 Cyclo G6 Glaucoma Laser Systems. These results are subject to final audit and completion of year-end financial reporting processes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IRIDEX Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9623251-en) on January 12, 2026, and is solely responsible for the information contained therein.